UBS analyst Kevin Caliendo raised the firm’s price target on Quest Diagnostics (DGX) to $220 from $210 and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $229 from $224 at Baird
- Quest Diagnostics price target raised to $245 from $225 at BofA
- Quest Diagnostics price target raised to $230 from $225 at Barclays
- Quest Diagnostics Lifts Outlook On Strong Earnings Call
- Quest Diagnostics price target raised to $225 from $210 at Evercore ISI